Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

University researchers hired several different animals to check whether they could disperse baobab's seeds through their ...

Happy 10th Birthday Ethereum, the SEC has honored you by giving the DeFi ecosystem the best gift ever - regulatory clarity - ...